Standard BioTools
LAB on XNAS, Standard BioTools Inc.
Measures activity, not value. Not investment advice.
Latest quarter (Jul 2026)
-0.9%
+0.8 pts vs its 3-year median
Sharp changes
8
quarterly revenue change, quarterly capital spending jump
What usually follows Revenue growth was not followed by a clear share-price difference over the next 6 months. No relationship found How we measured it
10-Q and 10-K figures, by the quarter they describe. Dashed: 3-year median.
See the numbers
| Quarter of Jul 2026: -0.9% |
| Quarter of Apr 2026: -7.6% |
| Quarter of Jan 2026: -48% |
| Quarter of Jul 2025: -57% |
| Quarter of Apr 2025: -42% |
| Quarter of Jan 2025: -10% |
| Quarter of Oct 2024: +66% |
| Quarter of Jul 2024: +77% |
| Quarter of Apr 2024: +34% |
| Quarter of Jan 2024: +81% |
| Quarter of Oct 2023: +4.3% |
| Quarter of Jul 2023: -1.1% |
| Quarter of Apr 2023: +47% |
| Quarter of Jan 2023: -5.2% |
| Quarter of Oct 2022: -29% |
| Quarter of Jul 2022: -10% |
| Quarter of Apr 2022: -39% |
| Quarter of Jan 2022: -19% |
| Quarter of Oct 2021: -14% |
| Quarter of Jul 2021: -28% |
| Quarter of Apr 2021: +19% |
| Quarter of Jan 2021: +19% |
| Quarter of Oct 2020: +38% |
| Quarter of Jul 2020: +50% |
| Quarter of Apr 2020: -7.6% |
| Quarter of Jan 2020: -8.3% |
| Quarter of Oct 2019: +0.4% |
| Quarter of Jul 2019: -8.5% |
| Quarter of Apr 2019: +6.7% |
| Quarter of Jan 2019: +19% |
| Quarter of Oct 2018: +17% |
| Quarter of Jul 2018: +17% |
| Quarter of Apr 2018: +11% |
| Quarter of Jan 2018: -1.1% |
| Quarter of Oct 2017: +11% |
What the numbers say
- Median revenue growth on a year earlier: -0.9% in the quarter from 1 Jul 2026 (3-year median -1.6%); the most since Oct 2024.
- 8 sharp changes in all loaded history (quarterly revenue change, quarterly capital spending jump).
- Median growth on a year earlier, latest complete quarter: the largest is Deferred revenue, -72%.
See the numbers
| Deferred revenue | -72% |
| Inventory | -31% |
| Contracted backlog | -8.9% |
| Revenue | -0.9% |
Every measure from this source
5 years, by the period each figure describes
Sharp changes
8 in all loaded history, strongest first
Standard BioTools reported revenue of $45.5M for the quarter ended 31 Mar 2024, 1.8× the same quarter last year.
Same quarter last year: $25.1M; its normal quarter is $26.1M.
See the evidence
- This period
- $45.5M (the quarter ended 31 Mar 2024)
- Normal quarter (median of 8 earlier)
- $26.1M
- Typical spread (median absolute deviation)
- $951K
- How far from its usual level
- +7.5
- Same quarter last year
- $25.1M
- History used
- 5,023 days
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Check it at the source: SEC EDGAR quarterly reports.
Standard BioTools reported revenue of $45.0M for the quarter ended 30 Sep 2024, 1.8× the same quarter last year.
Same quarter last year: $25.4M; its normal quarter is $27.3M.
See the evidence
- This period
- $45.0M (the quarter ended 30 Sep 2024)
- Normal quarter (median of 8 earlier)
- $27.3M
- Typical spread (median absolute deviation)
- $1.8M
- How far from its usual level
- +6.4
- Same quarter last year
- $25.4M
- History used
- 5,206 days
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Check it at the source: SEC EDGAR quarterly reports.
Standard BioTools reported revenue of $46.7M for the quarter ended 31 Dec 2024, 1.7× the same quarter last year.
Same quarter last year: $28.2M; its normal quarter is $27.9M.
See the evidence
- This period
- $46.7M (the quarter ended 31 Dec 2024)
- Normal quarter (median of 8 earlier)
- $27.9M
- Typical spread (median absolute deviation)
- $2.7M
- How far from its usual level
- +4.7
- Same quarter last year
- $28.2M
- History used
- 5,298 days
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Check it at the source: SEC EDGAR quarterly reports.
Standard BioTools reported revenue of $37.2M for the quarter ended 30 Jun 2024, 1.3× the same quarter last year.
Same quarter last year: $27.7M; its normal quarter is $26.3M.
See the evidence
- This period
- $37.2M (the quarter ended 30 Jun 2024)
- Normal quarter (median of 8 earlier)
- $26.3M
- Typical spread (median absolute deviation)
- $1.3M
- How far from its usual level
- +4.1
- Same quarter last year
- $27.7M
- History used
- 5,114 days
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Check it at the source: SEC EDGAR quarterly reports.
Standard BioTools reported revenue of $39.9M for the quarter ended 30 Sep 2020, 1.5× the same quarter last year.
Same quarter last year: $26.5M; its normal quarter is $28.6M.
See the evidence
- This period
- $39.9M (the quarter ended 30 Sep 2020)
- Normal quarter (median of 8 earlier)
- $28.6M
- Typical spread (median absolute deviation)
- $1.8M
- How far from its usual level
- +3.9
- Same quarter last year
- $26.5M
- History used
- 3,745 days
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Check it at the source: SEC EDGAR quarterly reports.
Standard BioTools reported revenue of $44.6M for the quarter ended 31 Dec 2020, 1.4× the same quarter last year.
Same quarter last year: $32.4M; its normal quarter is $29.2M.
See the evidence
- This period
- $44.6M (the quarter ended 31 Dec 2020)
- Normal quarter (median of 8 earlier)
- $29.2M
- Typical spread (median absolute deviation)
- $2.9M
- How far from its usual level
- +3.6
- Same quarter last year
- $32.4M
- History used
- 3,837 days
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Check it at the source: SEC EDGAR quarterly reports.
The records
One row per company, data through 1 Nov 2026
| Company | Sector | Latest quarter | vs year before |
|---|---|---|---|
| Standard BioTools | Health Care | $19.4M |